Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 5/20 | 1.00 |
| ▸ | OGG1 | O15527 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 7/20 | 0.59 |
| ▸ | BCHE | P06276 | 5/20 | 0.59 |
| ▸ | ACHE | P22303 | 5/20 | 0.59 |
| ▸ | RAD52 | P43351 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | UBE2N | P61088 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GBA1 | P04062 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | USP1 | O94782 | 1/20 | 0.54 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4867367 | 0.88 | PDE5A (0.78) | PDE5AOGG1APPBCHEACHE | |
| SCHEMBL4866829 | 0.88 | PDE5A (0.78) | PDE5AOGG1APPBCHEACHE | |
| SCHEMBL4856782 | 0.87 | PDE5A (0.77) | PDE5AOGG1APPBCHEACHE | |
| SCHEMBL4867046 | 0.85 | PDE5A (0.73) | PDE5AOGG1APPBCHEACHE | |
| SCHEMBL4861326 | 0.85 | PDE5A (0.73) | PDE5AOGG1APPBCHEACHE | |
| SCHEMBL4894324 | 0.85 | PDE5A (0.73) | PDE5AOGG1APPBCHEACHE | |
| SCHEMBL4864327 | 0.84 | PDE5A (0.72) | PDE5AOGG1APPBCHEACHE | |
| SCHEMBL4867110 | 0.83 | PDE5A (0.70) | PDE5AOGG1APPRAD52KMT2A | |
| SCHEMBL4868370 | 0.81 | PDE5A (0.68) | PDE5AAPPBCHEACHEALDH1A1 | |
| SCHEMBL4864401 | 0.79 | PDE5A (0.65) | PDE5AOGG1APPBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | claimed |
| JP-2008526734-A | — | — | 2008-07-24 | — | — | JP | claimed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2008-08-28 | — | — | US | disclosed |
| EP-1844023-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071095-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | SK CHEMICALS CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | PDE5A 1861/4885OGG1 2592/4885APP 1979/4885 |
| US-20080207614-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY | GPR119, GCKR, GLP1R | PDE5A 204/4885OGG1 3583/4885APP 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.